Clinical Trial of PM54 in Advance Solid Tumors Patients.
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The first part of the study (phase Ia - dose escalation) will evaluate the safety and
tolerability and identify the dose-limiting toxicities (DLTs) of PM54.
The second part of the study (phase Ib - expansion) will be to evaluate the antitumor
activity of PM54 in terms of clinical benefit (response or stable disease [SD] ≥4 months
associated with tumor shrinkage), according to the RECIST v.1.1 and/or serum markers as
appropriate, in patients with selected advanced solid tumors.